Takeda And Asuka Agree To Make ARB Blopress Generic
This article was originally published in PharmAsia News
In Japan, Takeda and Asuka have reached an agreement whereby the latter may sell a generic form of Takeda’s ARB Blopress (candesartan) with the same ingredients, additives, and productions methods as the forerunner drug, the companies announced on May 16.
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.